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ed March 19, 2013.he purpose of this study was to assess the safety and efﬁcacy of left atrial appendage (LAA) closure in nonvalvular
atrial ﬁbrillation (AF) patients ineligible for warfarin therapy.Background The PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation)
trial demonstrated that LAA closure with the Watchman device (Boston Scientiﬁc, Natick, Massachusetts) was
noninferior to warfarin therapy. However, the PROTECT AF trial only included patients who were candidates for
warfarin, and even patients randomly assigned to the LAA closure arm received concomitant warfarin for 6 weeks
after Watchman implantation.Methods A multicenter, prospective, nonrandomized study was conducted of LAA closure with the Watchman device in
150 patients with nonvalvular AF and CHADS2 (congestive heart failure, hypertension, age 75 years, diabetes
mellitus, and prior stroke or transient ischemic attack) score 1, who were considered ineligible for warfarin. The
primary efﬁcacy endpoint was the combined events of ischemic stroke, hemorrhagic stroke, systemic embolism,
and cardiovascular/unexplained death.Results The mean CHADS2 score and CHA2DS2-VASc (CHADS2 score plus 2 points for age 75 years and 1 point for vascular
disease, age 65 to 74 years, or female sex) score were 2.8  1.2 and 4.4  1.7, respectively. History of
hemorrhagic/bleeding tendencies (93%) was the most common reason for warfarin ineligibility. Mean duration of
follow-up was 14.4  8.6 months. Serious procedure- or device-related safety events occurred in 8.7% of patients
(13 of 150 patients). All-cause stroke or systemic embolism occurred in 4 patients (2.3% per year): ischemic stroke
in 3 patients (1.7% per year) and hemorrhagic stroke in 1 patient (0.6% per year). This ischemic stroke rate was less
than that expected (7.3% per year) based on the CHADS2 scores of the patient cohort.Conclusions LAA closure with the Watchman device can be safely performed without a warfarin transition, and is a reasonable
alternative to consider for patients at high risk for stroke but with contraindications to systemic oral anticoagulation.
(ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology [ASAP]; NCT00851578)
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arrhythmia, and increases the risk of ischemic stroke 5-fold
(1). AF-related ischemic stroke is associated with signiﬁcantgy Center, Mount Sinai School of Medicine,
of Leipzig Heart Center, Leipzig, Germany;
lka Hospital, Prague, Czech Republic;
Frankfurt, Germany; and kKrankenhaus der
ermany. Boston Scientiﬁc provided ﬁnancial
y, Mobius-Winkler, Neuzil, Schuler, Sick, and
d/or consulting fees from Boston Scientiﬁc, the
. Drs. Miller and Wiebe have reported that they
ontents of this paper to disclose.
, 2012; revised manuscript received March 13,morbidity, mortality, and healthcare expenditures (2–4).
Thus, prevention of cardioembolic stroke remains clinically
and economically important (5). Although oral anti-
coagulation with either warfarin or the more recently
introduced factor II/Xa inhibitors can signiﬁcantly reduce
the risk of stroke in at-risk patients with AF, these medica-
tions are associated with the potential for severe hemorrhagic
complications (6–9). As an alternative to systemic anticoag-
ulant therapy, the PROTECT AF (Watchman Left Atrial
Appendage System for Embolic Protection in Patients With
AF) clinical trial examined the hypothesis that the “local”
therapy of left atrial appendage (LAA) closure could reca-
pitulate the beneﬁts in stroke prevention observed with
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TIA = transient ischemic
attack
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2552warfarin. The Watchman device
proved to be noninferior to
warfarin in preventing stroke in
nonvalvular AF patients with
a CHADS2 (congestive heart
failure, hypertension, age 75
years, diabetes mellitus, and prior
stroke or transient ischemic attack)
score 1 (10). However, PRO-
TECTAF only included patients
who were candidates for either
therapy, and in patients ran-
domized to the LAA closure
arm, patients received concomi-
tant warfarin after Watchman
implantation for 6 weeks (11).
Thus, there are no data on thepotential use of the Watchman device in patients with
contraindications to warfarin. The nonrandomized ASAP
(ASA Plavix Feasibility Study With Watchman Left Atrial
Appendage Closure Technology) study was conducted to
assess the safety and efﬁcacy of LAA closure in nonvalvular
AF patients with a contraindication for warfarin therapy
(12,13). Patients only received antiplatelet agents after
Watchman implantation.
Methods
This was a multicenter prospective nonrandomized study of
LAA closure with the Watchman device (Boston Scientiﬁc,
Natick, Massachusetts) in patients with nonvalvular AF and
a CHADS2 score 1, who were ineligible for oral anti-
coagulation. Patients (N ¼ 150) were enrolled at 4 centers
between January 2009 and November 2011. The inclusion
criteria were age >18 years, nonvalvular AF (paroxysmal,
persistent, or permanent), CHADS2 score 1, a contrain-
dication for even short-term oral anticoagulation therapy,
and eligibility for 6 months of treatment with a thienopyr-
idine antiplatelet agent (clopidogrel or ticlopidine) and
lifelong aspirin. Contraindications for oral anticoagulant use
(based on the warfarin labeling) were categorized as: 1)
hemorrhagic/bleeding tendenciesddeﬁned as active peptic
ulcer disease or history of overt bleeding of the gastroin-
testinal, genitourinary, or respiratory tract; central nervous
system hemorrhage, cerebral aneurysms, dissection of the
aorta, pericarditis/pericardial effusions or bacterial endo-
carditis; 2) blood dyscrasias; 3) unsupervised patients with
senility and/or high fall risk; and 4) other documented
reason (including hypersensitivity to warfarin). Similar to the
PROTECT AF trial, the key exclusion criteria included left
ventricular ejection fraction <30%, intracardiac thrombus/
dense spontaneous contrast by transesophageal echocardi-
ography (TEE), a patent forman ovale with atrial septal
aneurysm, complex atheroma with mobile plaque in the
ascending aorta/aortic arch, signiﬁcant mitral stenosis, or an
existing pericardial effusion >3 mm (10). After approval bythe institutional review board, patients were enrolled with
written informed consent.
Implantation and follow-up. Heparin was administered to
a recommended active clotting time of 200 s to 300 s. Under
TEE and ﬂuoroscopic guidance, Watchman implantation
was performed as previously described (10). After device
implantation, subjects were followed up at 3, 6, 12, 18, and
24 months. A TEE was performed at 3 and 12 months to
assess device position, peri-device LAA ﬂow, and device-
related thrombus. The National Institutes of Health stroke
scale was administered by a neurologist at baseline, and at 3,
12, and 24 months (14). The Barthel index and modiﬁed
Rankin scale were administered at baseline and all follow-
ups. Following the Watchman implant, patients were ad-
ministered 6 months of a thienopyridine antiplatelet agent
(clopidogrel or ticlopidine) and lifelong aspirin.
Deﬁnitions. The CHADS2 score (scale 0 to 6) includes
congestive heart failure, hypertension, age 75 years, dia-
betes mellitus, and prior stroke or transient ischemic attack
(TIA [2 points]) (15). The CHA2DS2-VASc score (scale
0 to 9) includes the same components but with 2 points
for age 75 years and the addition of 1 point for vascular
disease, age 65 to 74 years, or female sex (16). The composite
primary efﬁcacy endpoint includes ischemic stroke, hemor-
rhagic stroke, systemic embolism, and cardiovascular/unex-
plained death. A serious adverse event includes any untoward
medical condition that results in death, was life-threatening,
required inpatient hospitalization or prolongation of
existing hospitalization, or resulted in persistent or signiﬁ-
cant disability/incapacity. An independent clinical events
committee adjudicated all adverse events.
Statistical methods. A sample size of as many as 150
enrolled subjects was determined based on the feasibility
nature of the study and was not calculated by statistical
means. The pre-deﬁned analysis reported here consists of all
subjects completing the 3-month follow-up visit. Incidence
rates are expressed as percentages or rates (per 100 patient-
years). Patient-years were calculated from the date of
implant attempt to either the event date, date of last known
status, or date of death.Results
Patient demographics, cardioembolic risk factors, and
follow-up compliance. The baseline characteristics of the
study population are shown in Table 1. The mean age was
72.5  7.4 years, 64% (n ¼ 96 of 150) were male. The most
common risk factor for stroke was hypertension (94.7%),
and 40% of patients previously had an ischemic stroke/TIA.
The mean CHADS2 score was 2.8  1.2, and 85%
of patients were CHADS2 2. The mean CHA2DS2-
VASC score was 4.4  1.7, and 95% of patients were
CHA2DS2-VASC 2. History of hemorrhagic/bleeding
tendencies (93%) was the most common reason for warfarin
ineligibility. The mean duration of follow-up was 14.4 
8.6 months, and the overall compliance with follow-up visits
Table 2 Procedural Details (N ¼ 150)
Procedure time, min 51.5  27.7
Implant success 142 (94.7%)
Implant failure 8 (5.3%)
Anatomical considerations* 7
Discontinued procedure (pericardial effusion) 1
Implanted device sizes
21 mm 23 (16.2%)
24 mm 46 (32.4%)
27 mm 40 (28.2%)
30 mm 26 (18.3%)
33 mm 7 (4.9%)
Values are mean  SD and n (%). *In these 7 cases, the devices were deployed but not released as
they did not meet the device release criteria, which include the following: 1) the implant is posi-
tioned at or slightly distal to and spans the entire left atrial appendage ostium; 2) the implant is
stable (by gentle tug test); 3) the implant size is appropriate once deployed; and 4) the implant
seals off the left atrial appendage from the left atrium (jet around the device <5 mm) and all lobes
are distal to implant.
Table 1 Clinical Characteristics and Stroke Risk (N ¼ 150)
Clinical
Age, yrs 72.5  7.4
Male 96 (64.0%)
Stroke risk factors*
Heart failure or reduced LVEF 43 (28.7%)
Hypertension 142 (94.7%)
Age 75 yrs 64 (42.7%)
Diabetes mellitus 48 (32.0%)
Prior stroke or TIA 61 (40.7%)
Vascular disease 27 (18.0%)




















Mean CHA2DS2-VASC score (entire cohort, N ¼ 150) ¼ 4.4  1.7
Reasons for warfarin ineligibility*
History of hemorrhagic/bleeding tendencies 140 (93.0%)
Blood dyscrasia 11 (7.3%)
Unsupervised senility/high fall risk 6 (4.0%)
Other 8 (5.3%)
Values are mean  SD and n (%). *Risk factors/reasons not mutually exclusive.
CHADS2 ¼ congestive heart failure, hypertension, age 75 years, diabetes mellitus, and prior
stroke or transient ischemic attack; CHA2DS2-VASC ¼ CHADS2 score plus 2 points for age 75
years and 1 point for vascular disease, age 65 to 74 years, or female sex; LVEF ¼ left ventricular
ejection fraction; TIA ¼ transient ischemic attack.
Table 3
Procedure and Device-Related Serious
Adverse Events (N ¼ 150)
Device embolization 2 (1.3%)
Pericardial effusion with tamponade (percutaneous drainage) 2 (1.3%)
Pericardial effusion, no tamponade (no intervention required) 3 (2.0%)
Device thrombus with ischemic stroke* 1 (0.7%)
Femoral pseudoaneurysm (surgically repaired) 1 (0.7%)
Femoral hematoma/bleeding 2 (1.3%)
Othery 3 (2.0%)
Total patients with procedure- and device-related SAEs 13 (8.7%)
Values are n (%). *Device thrombus and stroke occurred in a single patient, but is counted as 2
adverse events. yOral bleeding, n ¼ 1, and intraprocedural hypotension, n ¼ 2.
SAE ¼ serious adverse event(s).
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(43 of 43). Two patients (1.3%) were lost to follow-up, and
another 2 patients (1.3%) withdrew consent.
Procedural details. The mean procedure time was 51.5 
27.7 min. Successful device implantation occurred in 94.7%
(n ¼ 142 of 150) (Table 2). Failure to implant (n ¼ 8, 5.3%)
was due to anatomical considerations (n ¼ 7) or pericardial
tamponade (n ¼ 1). Of the former, the devices were intro-
duced but did not meet the device release criteria so were
removed. The distribution of successfully deployed devices is
shown in Table 2; the majority (60.6%) were either 24 mm
or 27 mm.
Procedure anddevice-related serious adverse events. Serious
procedure- or device-related safety events occurred in 8.7%
of patients (13 of 150) (Table 3). There were 2 cases of
pericardial effusion with tamponade requiring percutaneousdrainage (500 cc and 600 cc of blood were removed,
respectively). Neither patient required surgical intervention.
One of these patients subsequently underwent a successful
LAA closure procedure; in the other case, the procedure
was simply aborted. There were 3 additional cases of small/
mild pericardial effusion without tamponade not requiring
intervention. Device embolization occurred in 2 patients, both
immediately within the procedure itself. In both, the devices
embolized to the descending aorta, and were successfully
retrieved percutaneously with a vascular loop snare; neither
patient experienced immediate or long-term complications.
After removal, 1 patient subsequently underwent successful
implantation of a larger Watchman device.
There were 6 cases of device-related thrombus; only 1 was
adjudicated as a serious adverse event because only it
was associated with a stroke (341 days post-implant). The
remaining 5 cases were discovered during surveillance
TEEs (mean 164  135 days post-implant) without
clinical sequela. These 5 cases were conservatively managed:
4 received 4 to 8 weeks of low-molecular-weight heparin,
and 1 received no treatment.
Primary efﬁcacy outcomes. As shown in Table 4, after
176.9 patient-years of follow-up, all-cause stroke or systemic
embolism occurred in 4 patients (2.3% per year), ischemic
stroke in 3 patients (1.7% per year), and hemorrhagic stroke
Figure 1
Expected Annual Rate of Stroke Based on
CHADS2 Score
Gage 2004 (blue diamonds) (15); Gage 2001 (green triangles) (17). ASAP ¼ ASA
Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology;
CHADS2 ¼ congestive heart failure, hypertension, age 75 years, diabetes
mellitus, and prior stroke or transient ischemic attack.
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with a prior history of stroke or TIA. A total of 9 patients
(5.0% per year) died during the follow-up period (cardio-
vascular, n ¼ 3; cancer, n ¼ 2; other, n ¼ 4); none were
device or procedure related. The cardiovascular and non-
cardiovascular deaths occurred at a median of 406 and
209 days post-implant, respectively.
Comparison to expected annual stroke/TIA risk. The
mean CHADS2 score in the ASAP study population was
2.8, which equates to a predicted ischemic stroke rate of
7.4% per year using data from a cohort of hospitalized AF
patients, and assuming no aspirin use (17). If this expected
stroke rate of 7.4% per year is averaged with data in which
aspirin was used (15), the expected ischemic stroke of the
ASAP population is approximately 7.3% (Fig. 1). Thus, the
observed ischemic stroke rate of 1.7% per year (1-sided exact
upper 95% bound rate of 4.4%) represents 77% fewer events
than expected.
Clopidogrel has been reported to reduce ischemic stroke
by 32% (13). Thus, if one discounts the 7.3% rate by
32% (though clopidogrel or ticlopidine were only used for
6 months in the ASAP study), the expected stroke rate would
be 5.0% per year. But the observed rate of 1.7% per year would
still represent a 64% reduction in the ischemic stroke rate.
Discussion
This represents the ﬁrst prospective study of LAA closure
with the Watchman device in the clinically important
population of patients with contraindication to even short-
term oral anticoagulation therapy (18,19).
Main ﬁndings. On the basis of the thromboembolic risk
proﬁle (CHADS2 score 2.8) of the ASAP registry pop-
ulation, the annualized ischemic stroke rate was expected to
be 7.3% if treated with aspirin alone (15). However, the
observed rate in ASAP was only 1.7%, representing 77%
fewer events than expected. Patients in the ASAP study
also received concomitant treatment with clopidogrel for
6 months, and the ACTIVE A (Atrial Fibrillation Clopi-
dogrel Trial With Irbesartan for Prevention of Vascular
Events) study demonstrated that AF patients additionally
treated with life-long clopidogrel sustained fewer ischemic
strokes that those treated with aspirin alone (relative risk:
0.68; 95% conﬁdence interval: 0.57 to 0.80) (13,15).
Accordingly, if one discounts the expected stroke rate of thisTable 4 Clinical Outcomes
Entire Cohort
Events/Patient-Years*
Primary efﬁcacy 8/175.0 (4.6%)
Death, all cause 9/180.0 (5.0%)
All stroke 4/176.0 (2.3%)
Ischemic stroke 3/176.9 (1.7%)
Hemorrhagic stroke 1/179.1 (0.6%)
The primary efﬁcacy endpoint was deﬁned as the combined events of ischemic stroke, hemorrhagic
stroke, systemic embolism, and cardiovascular/unexplained death. *Events per 100 patient-years.CHADS2 score population by this 32% stroke beneﬁt (even
though the ASAP study patients did not receive life-long
clopidogrel, but rather, only 6 months), this would still
result in an expected ischemic stroke rate of 5.0%dagain,
the observed stroke rate of 1.7% represents 64% fewer events
than expected.
For patients randomly assigned to the device arm in the
PROTECTAF study, the annualized rates of all-cause stroke
and ischemic stroke were 2.3% and 2.2%, respectively. If one
excludes the procedure-related ischemic strokes observed in
PROTECT AF, this would translate to an annualized
ischemic stroke rate of 1.34% in the Watchman group.
(Although these procedure-related strokes are certainly rele-
vant when assessing the risk/beneﬁt ratio of Watchman
implantation in any given patient, these are technical issues
that are operator experience-related and when removed, allow
for a better understanding of the underlying scientiﬁc question
of the antistroke potential of LAA closure using various
periprocedure anticoagulation strategies.) Interestingly, the
annualized rates of all-cause stroke and ischemic stroke in the
ASAP registry (2.3% and 1.7%, respectively) was similar
despite the fact that the patients in the device arm of the
PROTECT AF study were additionally prescribed warfarin
during the 45-day transition period until the follow-up TEE.
This raises the possibility that this initial warfarin transition
may not provide a signiﬁcant beneﬁt even in those patients
able to tolerate short-term oral anticoagulation therapy. Of
course, this is only a hypothesis based on shorter-term follow-
up in theASAP registry, andmust be assessed in a prospective
clinical trial.
Stroke reduction in warfarin-ineligible patients. Until
recently, pharmacological strategies of reducing the risk
of stroke in high-risk patients considered unsuitable for
warfarin therapy have been only modestly effective. The
combination of aspirin and clopidogrel reduces the risk of
ischemic stroke (2.4% per year), compared with aspirin alone
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bleeding risk (2.0% vs. 1.3% per year, respectively) (13).
These results were reﬂected in the 2011 American College
of Cardiology Foundation/American Heart Association/
Heart Rhythm Society focused update on the management
of AF patients, which assigned a Class IIB recommendation
to the addition of clopidogrel in warfarin-ineligible
patients (20).
But this may change with the advent of novel oral anti-
coagulants. In the AVERROES (Apixaban Versus Ace-
tylsalicylic Acid to Prevent Strokes in Atrial Fibrillation
Patients Who Have Failed or Are Unsuitable for Vitamin K
Antagonist Treatment) study, warfarin-ineligible patients
were randomly allocated to either aspirin or the factor Xa
inhibitor, apixaban (21). The primary efﬁcacy endpoint of
stroke or systemic embolization was signiﬁcantly lower in
patients randomly assigned to apixaban (1.6% per year)
versus aspirin (3.7% per year; hazard ratio: 0.45, 95%
conﬁdence interval: 0.32 to 0.62; p < 0.001). Furthermore,
there were similar rates of major bleeding in the apixaban
(1.4% per year) and aspirin groups (1.2% per year; hazard
ratio: 1.13, 95% conﬁdence interval: 0.74 to 1.75; p ¼ 0.57).
Although apixaban has not yet been approved for clinical
use, on the one hand, this raises the question of exactly
which patients will be ineligible for oral anticoagulation
therapy and require LAA closure; and on the other hand:
1) the patients in the AVERROES study had a lower
CHADS2 score than those in the ASAP study (2.0 vs. 2.8,
respectively)da factor known to correlate with bleeding risk;
and 2) in the AVERROES study, even in the carefully
monitored setting attendant with a clinical trial, the rate of
permanent discontinuation of apixaban was 17.9% per year.
In addition, there are prior studies of percutaneous LAA
closure with the PLAATO (Percutaneous Left Atrial
Appendage Transcatheter Occlusion) device in warfarin-
ineligible patients. This device, which is no longer
commercially available, also supported the notion that LAA
closure in the absence of a warfarin transition can reduce
strokes in high-risk AF patients. The European PLAATO
study was a prospective, multicenter, nonrandomized study
of 180 nonrheumatic AF patients with CHADS2 scores 2
and contraindications to warfarin (22). After 129 patient-
years of follow-up, the annualized stroke rate in this
patient cohort was 2.3%, as compared with an expected rate
of 6.6%. Although the mean follow-up of this study was
only 9.6 months, there are 2 single-center reports of 5-year
follow-up data after LAA closure with the PLAATO
device. In the ﬁrst cohort of 64 patients, the annualized
stroke rate was 3.8% after PLAATO device implantation, as
compared with an expected stroke rate of 6.6%; in the
second cohort of 22 patients, the annualized stroke rate was
3.6% after PLAATO device implantation, as compared to
an expected stroke rate of 6.8% (23,24). It remains to be seen
whether this preservation of antistroke beneﬁt over longer
follow-up with the PLAATO device will also be realized
with the Watchman device.Safety. Serious procedure- or device-related safety events
occurred in 8.7% of patients (13 of 150 patients), which is
lower than that in the early PROTECT AF study cohort
(10.0%). The 2 most signiﬁcant safety events in the
PROTECT AF trial were pericardial tamponade related to
trauma during device implantation and procedure-related
stroke due to inadvertent introduction of air or thrombus
into the systemic circulation during device implantation.
The incidence of pericardial tamponade requiring interven-
tion was 5.0% in the PROTECT AF study, but with
operator experience, this decreased in the subsequent non-
randomized multicenter CAP (Continued Access Protocol)
registry to 2.2% (11). The ASAP tamponade rate (1.3%)
compares favorably; importantly, both patients were
successfully managed percutaneously. Procedure-related
stroke occurred in 1.1% of patients in the PROTECT AF
trial, but with operator experience, there were no procedure-
related strokes in the CAP registry (11) or in the ASAP
study. With careful sheath management during implanta-
tion, this complication appears to have largely been
eliminated.
Of the 150 patients enrolled in the ASAP registry, there
were 6 cases (4%) of device-related thrombus on the device
face, but only 1 resulted in clinical sequela (an ischemic
stroke). The remaining 5 thrombi were detected during
routine TEE screening. For comparison, in the PROTECT
AF study, device-associated thrombus was observed in 4.2%
(20 of 473) of successfully implanted patients, but only 3 had
an ischemic stroke; the other patients were either asymp-
tomatic or the thrombus resolved with anticoagulation
therapy. That translated to a device thrombus-associated
annualized stroke rate of 0.3% (11).
In the ASAP study, there were 2 instances (1.3%) of
device embolization to the aortadboth of which occurred
during the proceduredand were percutaneously snared and
removed. For comparison, of the 542 and 460 Watchman
patients enrolled in the PROTECT AF trial and the CAP
registry, the device embolized in 3 (0.6%) and 0 (0%)
patients, respectively. When all trials are combined, this
translates to an overall device embolization rate of 0.4%
(5 of 1,152 patients).
Similar to what was observed in the PROTECT AF and
CAP studies, there were no deaths related to the procedure
or to the device in the ASAP registry. For comparison,
in the European PLAATO study, 2 patients (1.1%) died
within 24 h of the procedure, and there were 6 cases of
cardiac tamponade (3.3%), of which 2 required surgery (22).
Study limitations. The prospective, nonrandomized design
of this study is inherently limited by the absence of a control
or alternative treatment group, and like all observational
studies is prone to selection bias. A randomized controlled
trial would be necessary to conﬁrm the favorable reductions
in ischemic stroke seen with LAA closure in warfarin-
ineligible patients. Furthermore, because newer oral antico-
agulant agents (e.g., apixaban, rivaroxaban, and dabigatran)
may be better tolerated by certain patients, a randomized
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drugs is necessary (25). The complication rate of Watchman
implantation may be higher in centers during their initial
learning curve than observed in this study. As with other
studies that have enrolled patients considered unsuitable for
warfarin, clinical judgment is often the ﬁnal determination of
whether a patient can safely or adequately take warfarin,
which can result in an overestimation of bleeding risk,
especially in the elderly. Finally, although the ASAP registry
was a prospective multicenter study with rigorous monitoring
and independent adjudication of all clinical events, it was
nonetheless not randomized and utilized historical control
data to predict the expected stroke rates.
Conclusions
Building upon the demonstration in the PROTECT AF
study that “local” therapy with LAA closure using the
Watchman device recapitulates the stroke prophylactic effect
of “systemic” therapy with oral anticoagulation therapy, the
ASAP registry has demonstrated that the Watchman device
can be safely implanted without a warfarin transition. That
allows the application of this therapy to the patient pop-
ulation at greatest clinical need for an alternative to oral
anticoagulation therapy: AF patients at high risk for stroke
but with contraindications to systemic oral anticoagulation.
Indeed, the recent 2012 European Society of Cardiology
guidelines for AF management have, for the ﬁrst time,
included percutaneous LAA closure therapy for stroke
prophylaxis in AF patientsdparticularly patients with
contraindications to chronic anticoagulation therapy (26).
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